In the spirit of Christ and the example of Francis of Assisi, the Mission of OSF HealthCare is to serve persons with the greatest care and love in a community that celebrates the Gift of Life.
For over 30 years, OSF HealthCare Cardiovascular Institute has conducted research trials at our Peoria and Rockford offices. The research trials study general cardiology, interventional cardiology, electrophysiology, heart failure, vascular care and cardiothoracic care. Many of our research trials are sponsored by international drug and device companies, while other trials are initiated by OSF Cardiovascular Institute providers.
All our studies are approved by the Peoria Institutional Review Board (IRB) at University of Illinois College of Medicine. The IRB is an ethical review board who protects human rights for those participating in research trials.
OSF Cardiovascular Institute is proud to contribute to medical care through our trials and be a part of many state-of-the-art treatments being approved by the Food and Drug Administration (FDA). Through our research, we can deliver the most appropriate and advanced treatment options to our patients.
If you are interested in learning more about research trial opportunities, please contact OSF Cardiovascular Institute at (800) 352-4410 or contact your current cardiovascular provider.
ARTEMIS: Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with Acute Myocardial Infarction.
BalanceD HF: Study to evaluate the effect of Balcinrenone/Dapagliflozin, compared with Dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired kidney function.
LEVEL: Study of Levosimendan in pulmonary hypertension patients with heart failure with preserved left ventricular ejection fraction.
LIBREXIA AF: Study to evaluate the efficacy and safety of Milvexian, an Oral Factor XIa Inhibitor, versus Apixaban in participants with atrial fibrillation.
LILAC: Study to evaluate the efficacy and safety of abeLacimab in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation.
REDEFINE HF: Randomized trial to determine the efficacy and safety of Finerenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated heart failure.
SOS-AMI: Selatogrel outcome study in suspected Acute Myocardial Infarction.
OASIS AMICS: Observational assessment of support with Impella best practices in acute myocardial infarction complicated by cardiogenic shock.
Optimizer PAS: Optimizer Smart Post Approval Study.
PROACTIVE HF: Safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III heart failure Patients
STEMI DTU: Primary unloading and delayed reperfusion in ST-Elevation Myocardial Infarction.
XTRACT: Registry assessing the clinical use of the Rotarex™ Rotational Excisional Atherectomy System.